Product Description
imaging agent for the treatment of adult patients with folate receptor-positive, platinum-resistant ovarian cancer (Sourced from: https://www.merck.com/news/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe/)
Mechanisms of Action: FR1 Imaging Agent
Novel Mechanism: Yes
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Ovarian Cancer
Phase 2: Pituitary Diseases|Renal Cell Carcinoma|Endometrial Cancer|Bladder Cancer|Ovarian Cancer|Pancreatic Cancer|Head and Neck Cancer|Testicular Cancer
Phase 1: Healthy Volunteers|Oncology Solid Tumor Unspecified|Endometrial Cancer|Ovarian Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PROCEED | P3 |
Terminated |
Ovarian Cancer |
2015-05-31 |
36% |
| EC20.11 | P1 |
Completed |
Healthy Volunteers |
2013-10-01 |
|
| EC-0489-01 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2011-12-01 |
|
| Pro00018123 | N/A |
Completed |
Osteoarthritis, Knee |
2011-10-01 |